Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Net Cash Flow (2019 - 2025)

Avidity Biosciences' Net Cash Flow history spans 7 years, with the latest figure at $32.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 121.53% year-over-year to $32.4 million; the TTM value through Dec 2025 reached $162.5 million, up 335.86%, while the annual FY2025 figure was $162.5 million, 335.86% up from the prior year.
  • Net Cash Flow reached $32.4 million in Q4 2025 per RNA's latest filing, down from $106.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $286.3 million in Q1 2024 to a low of -$221.7 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $3.2 million, with a median of $4.1 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1281.79% in 2021, then crashed 796.21% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$89.6 million in 2021, then surged by 319.61% to $196.7 million in 2022, then crashed by 49.45% to $99.4 million in 2023, then crashed by 251.18% to -$150.3 million in 2024, then soared by 121.53% to $32.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Net Cash Flow are $32.4 million (Q4 2025), $106.3 million (Q3 2025), and -$10.4 million (Q2 2025).